Table 3. Clinicopathological features of ESCC with or without methylation of PITX1.
| Characteristics | Total | Number of patients (%) | ||
|---|---|---|---|---|
| PITX1 | ||||
| Hypermethylated | Methylated | P-value | ||
| Number of patients | 40 | 13 (32.5) | 27 (67.5) | |
| Mean age ± SD (years) | 63.38 ± 12.26 | 70.74 ± 10.12 | 0.0388 | |
| Sex | ||||
| Male | 31 (77.5) | 8 (61.5) | 23 (81.2) | 0.0935 |
| Female | 9 (22.5) | 5 (38.5) | 4 (14.8) | |
| pT classification | ||||
| T1 | 13 (32.5) | 2 (15.4) | 11 (40.7) | 0.0017 |
| T2 | 6 (15.0) | 1 (7.7) | 5 (18.5) | |
| T3 | 15 (37.5) | 4 (30.8) | 11 (40.7) | |
| T4 | 6 (15.0) | 6 (46.1) | 0 (0.0) | |
| pN classification | ||||
| N0 | 18 (45.0) | 5 (38.4) | 13 (48.2) | 0.1507 |
| N1 | 12 (30.0) | 2 (15.4) | 10 (37.0) | |
| N2 | 6 (15.0) | 4 (30.8) | 2 (7.4) | |
| N3 | 4 (10.0) | 2 (15.4) | 2 (7.4) | |
| pM classification | ||||
| M0 | 37 (92.5) | 13 (100.0) | 24 (88.9) | 0.2114 |
| M1 | 3 (7.5) | 0 (0.0) | 3 (11.1) | |
| Cancer stage | ||||
| I | 13 (32.5) | 3 (23.1) | 10 (37.0) | 0.0053 |
| II | 11 (27.5) | 1 (7.7) | 10 (37.0) | |
| III | 13 (32.5) | 9 (69.2) | 4 (14.8) | |
| IV | 2 (5.0) | 0 (0.0) | 3 (11.1) | |
| Tumor location | ||||
| Upper thoracic | 12 (30.0) | 3 (23.1) | 9 (33.4) | 0.5981 |
| Middle thoracic | 17 (42.5) | 7 (53.8) | 10 (37.0) | |
| Lower thoracic | 11 (27.5) | 3 (23.1) | 8 (29.6) | |